CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Revenues
Total revenues	$ 3,431,420	$ 13,367,443
Total cost of revenues	2,414,541	7,834,011
Gross profit	1,016,879	5,533,432
Operating expenses:
Selling, general and administrative	11,447,894	12,751,644
Research and development	3,593,750	3,735,078
Total operating expenses	15,041,644	16,486,722
LOSS FROM OPERATIONS	(14,024,765)	(10,953,290)
Interest income	176,301	75,332
Transaction costs allocated to warrant liabilities	(633,198)
Unrealized gain on change in fair value of warrants classified as a liability	9,430,000	854,400
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification	(394,000)
Loss on issuance of warrants	(1,633,767)
Other (expense) income, net	(8,877)	642
Loss before provision for income taxes	(7,088,306)	(10,022,916)
Provision for income taxes	0	0
NET LOSS	(7,088,306)	(10,022,916)
Less: Net loss attributable to noncontrolling interest	95,785	75,857
NET LOSS attributable to Applied DNA Sciences, Inc.	(6,992,521)	(9,947,059)
Deemed dividend related to warrant modifications	(233,087)
NET LOSS attributable to common stockholders	$ (7,225,608)	$ (9,947,059)
Net loss per share attributable to common stockholders-basic (in dollars per share)	$ (1.82)	$ (15.21)
Net loss per share attributable to common stockholders-diluted (in dollars per share)	$ (1.82)	$ (15.21)
Weighted average shares outstanding-basic (in shares)	3,966,026	653,771
Weighted average shares outstanding-diluted (in shares)	3,966,026	653,771
Product revenues
Revenues
Total revenues	$ 1,074,813	$ 1,218,185
Total cost of revenues	1,138,650	1,308,620
Service revenues
Revenues
Total revenues	1,038,677	996,866
Clinical laboratory service revenues
Revenues
Total revenues	1,317,930	11,152,392
Total cost of revenues	$ 1,275,891	$ 6,525,391